section name header

Pronunciation

aye-ZITH-roe-mye-sin

Classifications

Therapeutic Classification: agents for atypical mycobacterium, anti-infectives

Pharmacologic Classification: macrolides

Indications

REMS


Unlabeled Use:

Action

  • Inhibits protein synthesis at the level of the 50S bacterial ribosome.
Therapeutic effects:
  • Bacteriostatic action against susceptible bacteria.

Spectrum:

Pharmacokinetics

Absorption: Rapidly absorbed (40%) after oral administration. IV administration results in complete bioavailability.

Distribution: Widely distributed to body tissues and fluids. Intracellular and tissue levels exceed those in serum; low CSF levels.

Protein Binding: 7–51%.

Metabolism/Excretion: Mostly excreted unchanged in bile; 4.5% excreted unchanged in urine.

Half-Life: 11–14 hr after single dose; 2–4 days after several doses.

Time/Action Profile

(serum)

ROUTEONSETPEAKDURATION
POrapid2.5–3.2 hr24 hr
IVrapidend of infusion24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Most Respiratory and Skin Infections

Otitis Media

Acute Bacterial Exacerbations of Chronic Bronchitis

Community-Acquired Pneumonia

Pelvic Inflammatory Disease

Endocarditis Prophylaxis

Nongonococcal Urethritis, Cervicitis, Chancroid, Chlamydia

Gonorrhea

Prevention of Disseminated MAC Infection

Cystic Fibrosis

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zithromax, Zmax

Pill Image

azithromycin_195-9012.jpg
azithromycin_195-9013.jpg